Arsenic trioxide for the treatment of myelodysplastic syndromes

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 613-621

  Vey, Norbert ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Arsenic trioxide; Chemotherapy; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; ASCORBIC ACID; AZACITIDINE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; RETINOIC ACID; SEMAXANIB; THALIDOMIDE; THIOL DERIVATIVE; TOPOTECAN; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ATRIOVENTRICULAR BLOCK; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DYSESTHESIA; DYSPNEA; EDEMA; FATIGUE; FEVER; HEADACHE; HEMATOPOIESIS; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; INSOMNIA; LEUKOCYTOSIS; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PRURITUS; QT PROLONGATION; REVIEW; RIGOR; SCORING SYSTEM; SORE THROAT; SURVIVAL RATE; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ARSENICALS; CLINICAL TRIALS, PHASE II; HUMANS; MYELODYSPLASTIC SYNDROMES; OXIDES; TREATMENT OUTCOME;

EID: 1542609975     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.613     Document Type: Review

References (65)

1. WAXMAN S, ANDERSON KC: History of the development of arsenic derivatives in cancer therapy. Oncologist (2001) 6:3-10.
2. CUTLER E, BRADFORD E: Action of iron, cod-liver oil, and arsenic on the globular richness of the blood? Am. J. Med. Sci. (1878) 75:74-84.
3. SHEN ZX, CHEN GQ, NI JH et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 89:3354-3360.
4. SOIGNET SL, MASLAK P, WANG ZG et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. (1998) 339:1341-1348.
5. SOIGNET SL, FRANKEL SR, DOUER D et al.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. (2001) 19:3852-3860.
6. COHEN MH, HIRSCHFELD S, FLAMM HONIG S et al.: Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist (2001) 6:4-11.
7. MILLER WH, JR., SCHIPPER HM, LEE JS, SINGER J, WAXMAN S: Mechanisms of action of arsenic trioxide. Cancer Res. (2002) 62:3893-3903.
8. WILLIAMSON PJ, KRUGER AR, REYNOLDS PJ, HAMBLIN TJ, OSCIER DG: Establishing the incidence of myelodysplastic syndrome. Br. J. Haematol. (1994) 87:743-745.
9. BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. (1982) 51:189-199.
10. FENAUX P, MOREL P, ROSE C et al.: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol. (1991) 77:497-501.
11. GREENBERG P, COX C, LEBEAU MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079-2088.
12. CHESON BD, BENNETT JM, KANTARJIAN H et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 96:3671-3674.
13. HELLSTROM-LINDBERG E, AHLGREN T, BEGUIN Y et al.: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythyropoietin: Results from a randomized Phase II study and long-term follow-up of 71 patients. Blood (1998) 92:68-75.
14. NEGRIN RS, HAEUBER DH, NAGLER A et al.: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood (1990) 76:36-43.
15. HELLSTROM-LINDBERG E, GULBRANDSEN N, LINDBERG G et al.: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor. significant effects on quality of life. Br. J. Haematol. (2003) 120:1037-1046.
16. DE WITTE T, ZWAAN F, HERMANS J et al.: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) [see comments]. Br. J. Haematol. (1990) 74:151-155.
17. DEEG HJ, SHULMAN HM, ANDERSON JE et al.: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood (2000) 95:1188-1194.
18. HELLSTROM-LINDBERG E, ROBERT KH, GAHRTON G et al.: A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br. J. Haematol. (1992) 81:503-511.
19. MILLER KB, KIM K, MORRISON FS et al.: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study. Ann. Hematol. (1992) 65:162-168.
20. DE WITTE T, SUCIU S, PEETERMANS M et al.: Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia (1995) 9:1805-1811.
21. ESTEY E, THALL P, BERAN M et al.: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood (1997) 90:2969-2977.
22. BERAN M, SHEN Y, KANTARJIAN H et al.: High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens. Cancer (2001) 92:1999-2015.
23. BERAN M, ESTEY E, OBRIEN S et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin. Oncol. (1999) 17:2819-2830.
24. WATTEL E, SOLARY E, LELEU X et al.: A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia (1999) 13:524-529 [In Process Citation].
25. DE WITTE, T, VAN BIEZEN A. HERMANS J et al.: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood (1997) 90:3853-3857.
26. OOSTERVELD M, MUUS P, SUCIU S et al.: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia (2002) 16:1615-1621.
27. LIST A, BERAN M, DIPERSIO J et al.: Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia (2003) 17:1499-1507.
28. CLARK RE, JACOBS A, LUSH CJ, SMITH SA: Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet (1987) 1:763-765.
29. GOLD EJ, MERTELSMANN RH, ITRI LM et al.: Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat. Rep. (1983) 67:981-986.
30. PICOZZI VJ, JR., SWANSON GF, MORGAN R, HECHT F, GREENBERG PL: 13-cis retinoic acid treatment for myelodysplastic syndromes. J. Clin. Oncol. (1986) 4:589-595.
31. KOEFFLER HP, HEITJAN D, MERTELSMANN R et al.: Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood (1988) 71:703-708.
32. AGUAYO A, KANTARJIAN HM, ESTEY EH et al.: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer (2002) 95:1923-1930.
33. AGUAYO A, KANTARJIAN H, MANSHOURI T et al.: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 96:2240-2245.
34. ZORAT F, SHETTY V, DUTT D et al.: The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. (2001) 115:881-894.
35. RAZA A, MEYER P, DUTT D et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood (2001) 98:958-965.
36. GILES FJ, STOPECK AT, SILVERMAN LR et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood (2003) 102:795-801.
37. GILES FJ: New drugs in acute myeloid leukemia. Curr. Oncol. Rep. (2002) 4:369-374.
38. DASKALAKIS M, NGUYEN TT, NGUYEN C et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood (2002) 100:2957-2964.
39. LUBBERT M, WIJERMANS P, KUNZMANN R et al.: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. (2001) 114:349-357.
40. SILVERMAN LR, DEMAKOS EP, PETERSON BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J. Clin. Oncol. (2002) 20:2429-2440.
41. WIJERMANS P, LÜBBERT M, VERHOEF G et al.: Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter Phase II study in elderly patients. J. Clin. Oncol. (2000) 18:956-962.
42. KORNBLITH AB, HERNDON JE 2nd, SILVERMAN LR et al.: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: A Cancer and Leukemia Group B study. J. Clin. Oncol. (2002) 20:2441-2452.
43. CHEN GQ, SHI XG, TANG W et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 89:3345-3353.
44. LEHMANN S, BENGTZEN S, PAUL A, CHRISTENSSON B, PAUL C: Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: Studies of cytotoxicity, apoptosis and the pattern of resistance. Eur. J. Haematol. (2001) 66:357-364.
45. CHEN YC, LIN-SHIAU SY, LIN JK: Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell. Physiol. (1998) 177:324-333.
46. CAI X, SHEN YL, ZHU Q et al.: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia (2000) 14:262-270.
47. DAVISON K, COTE S, MADER S, MILLER WH: Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia (2003) 17:931-940.
48. YANG CH, KUO ML, CHEN JC, CHEN YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. J. Cancer (1999) 81:796-799.
49. DAI J, WEINBERG RS, WAXMAN S, JING Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood (1999) 93:268-277.
50. GRAD JM, BAHLIS NJ, REIS I et al.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood (2001) 98:805-813.
51. LING YH, JIANG JD, HOLLAND JF, PEREZ-SOLER R: Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. (2002) 62:529-538.
52. PERKINS C, KIM CN, FANG G, BHALLA KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP Bcl-2, or Bcl-x(L). Blood (2000) 95:1014-1022.
53. MATHAS S, LIETZ A, JANZ M et al.: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis, Blood (2003) 102:1028-1034.
54. LEW Y, BROWN S, GRIFFIN R, SONG C, KIM J: Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. (1999) 59:6033-6037.
55. ROBOZ GJ, DIAS S, LAM G et al.: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium, and may exert an antileukemic effect via inhibition of angiogenesis. Blood (2000) 96:1525-1530.
56. PARK JW, CHOI YJ, JANG MA et al.: Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. (2001) 286:726-734.
57. PARK WH, SEOL JG, KIM ES et al.: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. (2000) 60:3065-3071.
58. SOIGNET S, AL E: A clinical and pharmacologic study of arsenic trioxide (ATO). Cancer Res. (2000) 41:543 (Abstract)
59. BARBEY JT, SOIGNET S: Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med. (2001) 135:842-843.
60. BARBEY JT, PEZZULLO JC, SOIGNET SL: Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J. Clin. Oncol. (2003) 21:3609-3615.
61. CAMACHO LH, SOIGNET SL, CHANEL S et al.: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol. (2000) 18:2620-2625.
62. VEY N, DREYFUS F, FENAUX P et al.: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a Phase I/2 study. Hematol. J. (2003) 4:218 (Abstract).
63. ELLISON R, KIRKAHART B, SINGER J: Updated safety experience with Trisenox (arsenic trioxide) injection. Hematol. J. (2003) 4:216.
64. LIST A, SCHILLER G, MASON J, DOUER D, ELLISON R: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary findings in a Phase II clinical study. Hematol. J. (2003) 4:218 (Abstract).
65. ALBITAR M, MANSHOURI T, SHEN Y et al.: Myelodysplastic syndrome is not merely 'preleukemia'. Blood (2002) 100:791-798.